Wird geladen...
Predicting Corticosteroid Free Endoscopic Remission with Vedolizumab in Ulcerative Colitis
BACKGROUND: Vedolizumab is an effective therapy for ulcerative colitis (UC), but costly and slow to work. New clinical responses occur after 30 weeks of therapy. AIMS: We aimed to enable physicians, patients, and insurers to predict whether a patient with UC will respond to vedolizumab at an early t...
Gespeichert in:
| Veröffentlicht in: | Aliment Pharmacol Ther |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5814341/ https://ncbi.nlm.nih.gov/pubmed/29359519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14510 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|